STK-026 / Synthekine - LARVOL DELTA

STK-026, a detoxified IL-12 partial agonist is well-tolerated and sustains CD8+ T cell activity with repeat doses in cynomolgus macaques (SITC 2024) - "All in vivo protocols were approved by a local Institutional Animal Care and Use Committee, or other appropriate review board, before study execution. All animals were housed in accordance with local regulations."

Oncology • CD4 • CD8 • GZMB • IFNG • IL12A • PD-1

Gradual lymphocyte activation with IL-12 partial agonist STK-026 maintains anti-tumor efficacy but escapes acute NK-mediated cytokine release and toxicities associated with WT IL-12 (SITC 2024) - "All in vivo protocols were approved by a local Institutional Animal Care and Use Committee, or other appropriate review board, before study execution. All animals were housed in accordance with local regulations."

Clinical • Oncology • CD8 • IFNG • IL12A • IL6 • TNFA

Synthekine Announces Presentation...at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (Businesswire) - "The company will also present two posters for STK-026, a biased IL-12 cytokine partial agonist. The preclinical data to be presented demonstrates STK-026 is engineered to retain the potent antitumor activity of IL-12 while avoiding its systemic toxicities. In addition, results of a GLP toxicology study in cynomolgus monkeys showed excellent tolerability of STK-026 and confirmed its preferential activity toward CD8 T cells. Relative to therapies based on unmodified IL-12, STK-026 is tuned to bias immune activation toward the adaptive and away from the innate immune systems, thus avoiding NK cell mediated dose-limiting toxicities that are the hallmark of IL-12 therapy, including cytokine release syndrome (CRS), hepatoxicity, and lymphopenia."

Preclinical • Oncology

Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window (SITC 2023) - "Similarly, human STK-026 avoided early spikes of NK activity in cynomolgus macaques and showed reduced signs of systemic toxicities compared to hIL-12wt-Fc. These data suggest that STK-026 is a novel immunotherapy approach with the potential to maintain anti-tumor efficacy while avoiding dose limiting toxicities classically associated with IL-12 therapy."

PK/PD data • Preclinical • Oncology • CD8 • IL12A • IL6 • TNFA

Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window (Businesswire) - "Synthekine...presented new data from preclinical studies of STK-026, its biased IL-12 partial agonist program, during the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting....In tumor bearing mouse models, a mouse surrogate of STK-026 was well-tolerated and showed meaningful anti-tumor efficacy as both a single agent and in combinations. Notably, compared to wild-type IL-12 treatment, STK-026 monotherapy demonstrated a substantial improvement in therapeutic window which was associated with reduced NK activation and systemic cytokine induction."

Preclinical • Oncology

Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs (Businesswire) - "Synthekine...announced that two poster presentations showcasing its next series of oncology programs will be delivered at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023....'We are also introducing STK-026, our IL-12 partial agonist program, which is currently in IND-enabling studies and shows promise as a potent immunotherapy for the treatment of cancer'....In preclinical models, a mouse surrogate of STK-026 retained anti-tumor efficacy without induction of severe toxicities and spike in NK cell activation associated with wild-type mouse IL-12 treatment....These data suggest IL-12 partial agonists may represent a novel immunotherapy approach to maintain efficacy while avoiding classical toxicity associated with IL-12 therapy."

Preclinical

Synthekine Licenses Additional Cytokine Programs (Businesswire) - “Synthekine…announced a new agreement with Stanford University to license cytokine partial agonist programs for IL-10, IL-12 and IL-22. These programs augment a growing pipeline of selective cytokine partial agonists at Synthekine that is maturing toward clinical development…Synthekine plans to leverage discoveries in IL-12, recently published in the journal Cell, to develop potential treatments for cancer…”

Licensing / partnership • Oncology